Circulating Tumor Cell is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Zhita Chen
Sun Yat-sen University First Affiliated Hospital

tielong Wang
Sun Yat-sen University First Affiliated Hospital

Chuanbao Chen
Sun Yat-sen University First Affiliated Hospital

Xitao Hong
Sun Yat-sen University First Affiliated Hospital

Jia Yu
Sun Yat-sen University First Affiliated Hospital

Yihao Ma
Sun Yat-sen University First Affiliated Hospital

Yiwen Guo
Sun Yat-sen University First Affiliated Hospital

Changjun Huang
Sun Yat-sen University First Affiliated Hospital

Xiaoshun He
Sun Yat-sen University First Affiliated Hospital

Weiqiang Ju
Sun Yat-sen University First Affiliated Hospital

Maogen Chen (chenmg3@mail.sysu.edu.cn)
Sun Yat-sen University First Affiliated Hospital  https://orcid.org/0000-0001-9319-5334

Research Article

Keywords: circulating tumor cells, radiofrequency ablation, hepatocellular carcinoma, recurrence

DOI: https://doi.org/10.21203/rs.3.rs-442626/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction:

It is of great significance to confirm reliable indicators for the guidance of pretransplant radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). In this study, we aim to investigate whether circulating tumor cell (CTC) status is a clinical indicator for RFA before liver transplantation (LT) in HCC patients.

Method:

79 HCC patients with pretransplant CTC analysis were enrolled in this retrospective study. Clinical outcomes including recurrence and survival were compared and analyzed between patients with and without pretransplant RFA.

Result

Forty-two patients were detected as CTC-positive and 18 patients received pretransplant RFA. Recurrence was correlated with CTC count \( (P = 0.024) \), tumor number \( (P = 0.035) \), liver cirrhosis \( (P = 0.001) \), Milan criteria \( (P = 0.003) \) and University of California San Francisco (UCSF) criteria \( (P = 0.001) \). Kaplan-Meier analysis revealed that patients with CTC-positive had a higher recurrence rate \( (P = 0.0257) \). For CTC-positive patients, the recurrence rate of pretransplant RFA group was significantly lower than non-pretransplant RFA group \( (0 \text{ vs. } 46.7\%, P = 0.0236) \). For CTC-negative patients, both recurrence rate and OS rate were similar and without significantly differences. In multivariate analysis, pretransplant RFA was the independent factor for recurrence \( (P = 0.025) \).

Conclusion

Pretransplant CTC status can guide the administration of pretransplant RFA in HCC patients which can reduce recurrence in CTC-positive HCC patients.

Introduction

Hepatocellular carcinoma (HCC) is regarded as the most common malignancy and is a leading cause of cancer-related death in the world as the 6th most common worldwide and 4th leading cancer-related death\(^1,2\). In China, HCC is the fourth most diagnosed cancers and the fourth leading cause of cancer death\(^3\). Treatment of HCC should be carefully selected to achieve promising outcomes. Hepatic resection (HR) is considered as the first-line treatment for patients without vasculature invasion in China\(^4,5\). However, the numbers of patients who are suitable for radical resection are limited and the overall 5-year recurrence rate remains high\(^6\). Liver transplantation (LT) has been accepted as the most effective and
curative treatment for patients with both HCC and decompensated cirrhosis. In patients for whom transplantation is not an option (Tumor size and numbers is beyond Milan criteria), local and systemic treatment are available as bridging therapy for HCC. Thermal ablation, for example, radiofrequency ablation (RFA), is considered as the preferred treatment for local tumor control and used for bridging or downstaging HCC patients before LT. However, the current clinical use of RFA depends on the experiences based on the traditional tumor characteristics, like tumor size, tumor numbers, and alpha-fetoprotein (AFP), and it remains controversial that whether patients will benefit from pretransplant RFA. Therefore, it is of great significance to confirm reliable indicators for the guidance of pretransplant RFA for HCC.

Our previous study confirmed that positive circulating tumor cell (CTC) count (≥1/3.2ml) was related to the early recurrence of patients with HCC after LT and showed that pretransplant CTC status may be useful to predict recurrence. Whether it also be useful to guide the application of pretransplant RFA remains unclear. In this study, we aim to investigate whether CTC status is clinical indicator for RFA before LT in patients with HCC.

Materials And Methods

Patient enrollment

Between January 2016 and January 2020, 713 patients received LT in our center and 373 patients met inclusion criteria. The inclusion criteria were as follows: 18 to 75 years of age, a diagnosis of HCC confirmed by postoperative pathological examination, and follow-up of more than 1 year. The exclusion criteria were as follows: patients with perioperative or nonrecurrence-related mortality, a diagnosis of other types of tumors, and follow-up of less than 1 year (Figure 1). Afterwards, 79 patients who were tested for CTCs were enrolled in this study. Eighteen patients only received pretransplant -RFA 6 months before LT.

All the procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. The study was approved by the Institutional Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University and informed consent waiver was granted by the IEC given the retrospective, minimal risk nature of the study. No organs from executed prisoners were transplanted into any of the patients reported in this study.

Perioperative management and Follow-up

The immunosuppressive regimen after LT was tacrolimus (Tac)+mycophenolate mofetil (MMF). The followed-up period was at least 1 year. Postoperative visits were performed on postoperative day (POD) 1-7, POD14 and each postoperative month (POM). Laboratory tests, imaging examinations and tumor markers were documented. Routine Doppler ultrasound of the liver graft blood flow and biliary tract was
performed once every 2 days for 7 days. Afterward, imaging studies were performed based on patients' clinical status or laboratory findings. HCC recurrence was diagnosed according to Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 edition) in China\textsuperscript{14}. For deceased patients/patients with recurrences, the date of death/recurrence was used as the last follow-up for overall survival (OS) and progression-free survival (PFS), respectively. The follow-up deadline was January 1\textsuperscript{st}, 2021.

**CTCs detection**

The specific method has been described in the previous study\textsuperscript{13}. In brief, the samples (3.2ml peripheral blood collected from median cubital vein) for CTCs analysis were collected within 1 month before LT. Negative enrichment and imFISH methods were introduced to detect CTCs. The identification of enriched CTCs was performed by imFISH, which combined the FISH probes with chromosome 8 (orange) centromere probes (Abbott Molecular Diagnostics, Des Plaines, IL, USA) and anti-CD45 monoclonal antibodies (Red, Cyttel). To be considered positive, CTCs needed to be hyperdiploid and have the phenotype CEP8+/DAPI+/CD45-.

**RFA procedures**

Indications for pretransplant RFA was evaluated by physicians primarily\textsuperscript{15}. Briefly, artificial ascites was created firstly by injecting with 100ml 5% glucose solution to separate gastrointestinal tract and liver. An 18G biopsy needle was used for biopsy of lesion sent for pathological examination. Afterward, the lesions were ablated with anhydrous alcohol and injected with 3ml anhydrous alcohol by 21G PTC needle. RFA was then performed with Cool-tip\textsuperscript{TM} electrode needle (ACT2020) for 10-30 minutes. The primary endpoint of RFA is to obtain a complete necrosis of liver tumors and create a safety margin of at least 10mm round the external margin of the lesion. Contrast enhanced ultrasound (CEUS) was performed on the second day after ablation to confirm the margin of tumor necrosis.

**Statistical analysis**

All statistical analyses of the data were performed by SPSS version 26.0. All data are expressed as the number and percentage of patients. For comparison between groups, the chi-square and Fisher’s exact tests were performed for frequencies and continuous data, respectively. Cox proportional hazards model was performed for multivariate analysis. Overall and disease-free survival were compared using the Kaplan–Meier method. A $P$-value<0.05 was considered statistically significant.

**Results**

**Baseline characteristics of patients with HCC in CTC-test group**

To eliminate selection bias, we compared baseline data between CTC-test group and no CTC-test group (Supplementary Table 1) and there were no significant differences in age, gender, AFP, diagnosis with cirrhosis and TNM staging between groups ($P$>0.05). Baseline characteristics of 79 patients enrolled in
this study are presented in Table 1. The median follow-up time was 15.7 and 17.3 months for PFS and OS, respectively. Of the 79 patients, 42 patients (53.2%) were detected as CTC-positive (1/3.2ml) and 18 (22.8%) patients received pretransplant RFA only. Fifteen patients (19.0%) had multinodular tumors and 31 (39.2%) patients had tumor with larger size (≥3cm). Most patients were diagnosed with Liver cirrhosis (92.4%) and Hepatic B virus (HBV) infection.

CTC result is related with the early recurrence of patients with HCC after LT

Analysis of the 79 patients revealed that 20 (25.3%) patients had a recurrence after LT (Table 2). Fifteen of 20 (75%) patients with recurrence and 27 of 59 (45.7%) patients without recurrence were positive for CTCs, respectively. The results showed that recurrence was correlated with CTC count ($\chi^2=5.128, P=0.024$), tumor number ($\chi^2=4.464, P=0.035$), liver cirrhosis ($\chi^2=11.559, P=0.001$), Milan criteria ($\chi^2=8.773, P=0.003$) and University of California San Francisco (UCSF) criteria ($\chi^2=10.225, P=0.001$), while there were no significant differences in other groups like preoperative AFP ($\chi^2=1.328, P=0.249$). Kaplan-Meier analysis revealed that patients with CTC-positive had higher recurrence rate compared with patients with CTC-negative ($P=0.0257$; Figure 2A). However, OS rate seemed to be similar and not significantly different between CTC-negative and CTC-positive groups ($P=0.5543$, Figure 2B).

Pretransplant RFA reduces recurrence in CTC-positive patients

Baseline characteristics in HCC patients with or without RFA were shown in Table 3 and no significantly differences were found between groups. The association between pretransplant RFA and posttransplant tumor recurrence was analyzed in HCC patients stratified be CTC status. During the follow-up period, recurrence was observed in 15 of 42 CTC-positive patients and 5 of 37 CTC-negative patients, respectively. For CTC-positive patients, the recurrence rate of pretransplant RFA group were significantly lower than non-RFA group (0 vs. 53.3%, $P=0.0236$; Figure 2C), whereas the OS rates between the groups were similar (87.5% vs. 83.3%, $P=0.5543$; Figure 2D). For CTC-negative patients, both recurrence rate and OS rate were similar and without significantly differences ($P=0.6636$ and 0.0677, respectively; Figure 2E-F).

Furthermore, the predictive value of CTC-positive for benefit of pretransplant RFA was evaluated within clinical subgroups (Figure 3). The result showed that the recurrence rates were lower in patients with pretransplant RFA. However, no significantly differences were found between patients with/without pretransplant RFA in these subgroups. Kaplan-Meier survival analyses for clinical subgroups are shown in Figure 3A-H. The efficacy of RFA to recurrence rate and OS in CTC-positive HCC patients were also evaluated in multivariate analysis. The result showed that pretransplant RFA was the independent factor for recurrence but not for OS ($P=0.025$ and 0.382, respectively; Table 4).

Discussion
LT has been regarded as the only curative method for patients with HCC. However, posttransplant tumor recurrence was the major limitation for the survival of these patients\textsuperscript{16, 17}. RFA is widely used for bridging or downstaging HCC patients before LT\textsuperscript{18}. It remains controversial that whether patients will benefit from pretransplant RFA for the lack of reliable indicators\textsuperscript{19-21}. In this retrospective study, we aimed to investigated whether CTC result could indicate the application of pretransplant RFA for HCC patients. Overall, our result showed that pretransplant RFA reduces recurrence effectively in CTC-positive patients with HCC. However, For CTC-negative patients, pretransplant RFA cannot reduce both recurrence rate and OS rate. Therefore, pretransplant CTC result may be used as an indicator for RFA before LT for patients with HCC.

Recurrences is the most negative factor affecting survival for LT patients with HCC\textsuperscript{7, 22}. The main cause of recurrence is tumor cell dissemination via blood vessel infiltration\textsuperscript{23}. In our study, recurrence after LT was related with CTC count, Milan criteria and UCSF criteria. The recurrence of LT within the Milan criteria was 13.0\%, and it is better than 43.6\% for those beyond Milan criteria. The recurrence of LT within the UCSF criteria was 13.7\% and it is also better than 46.4\% for those beyond UCSF criteria. This indicates that Milan criteria and UCSF criteria are the promising criteria for favorable outcomes\textsuperscript{24-26}. However, in China, patients tend to have HR or conservative treatment due to economic or ideological reasons, even if tumors are detected early. LT would be considered only when other treatments were ineffective or if the tumor progressed. Therefore, finding a method to predict the prognosis after LT is of great significance. CTCs were first discovered and described by Ashworth et al. in 1869\textsuperscript{27}. Vona et al. first explored the prognostic value of blood CTCs in patients with HCC and it was related with prognosis and recurrence in patients with HCC\textsuperscript{28}. CTC detection can be applied as a method for early cancer detection and prediction of recurrence or metastasis risk\textsuperscript{29-31}. Our previous study also revealed that CTC-positive patients had a worse prognosis after LT than those with CTC-negative\textsuperscript{13}. In current study, it remains unclear whether patients can benefit from RFA with achieving a high degree of tumor necrosis before LT\textsuperscript{32}. Agopian et al. showed in their study including 3601 recipients of LT that none of significantly differences were identified in survival between patients with/without locoregional treatment (LRT) prior to LT\textsuperscript{8}. Our resulted showed that pretransplant RFA reduces recurrence effectively in CTC-positive patients with HCC. However, in clinical subgroups significantly differences were not found between patients with/without pretransplant RFA. We consider these results in traditional clinical subgroups were not conflict with previous studies\textsuperscript{33, 34}, for CTC result is a novel biomarker to evaluate the risk of recurrence and may be a complementary biomarker of traditional clinical indicators to pretransplant RFA in HCC patients. It can be applied to the guidance for the downstaging treatment before LT\textsuperscript{35}. In addition, CTC result can be used to guide the pretransplant management for HCC patients. In our study, CTCs were detected in 42 of 79 (53.2\%) patients before LT. The sensitivity and specificity of CTCs detection were 75\% and 54.2\%, respectively. The results showed that CTCs test had good sensitivity and specificity so it could be helpful to predict recurrence. An additional pretransplant RFA may be not necessarily needed for CTC-negative patients. A further prospective, multicenter, and large population study is needed to investigate the value of CTC result as an indicator in guiding pretransplant treatment.
RFA was first applied and described by Rossi et al. in 1993\cite{36}. In China, the use of RFA for HCC was quickly developed in recent years. Compared with HR, RFA is minimally invasive and has lower morbidity and mortality rates, especially in cases with impaired liver functions. However, the tumor size and stage are important factors for the outcome of RFA\cite{37,38}. Yan et al. showed in their study that larger tumor size (≥5cm) would result in less complete necrosis rate and RFA alone for HCC is limited\cite{39}. The combination of RFA and other methods would have further benefit for patients. RFA can be used for bridging or downstaging HCC patients before LT therefore it may help to prolong time on waiting-list and reduce waiting-list mortality rate\cite{40}. The current clinical use of RFA depends on the experiences based on the traditional tumor characteristics and a novel biomarker to guide pretransplant treatment is of great significance. Our result showed that transplant RFA reduces recurrence rates effectively of patients in the status of CTC-positive. For CTC-negative patients, pretransplant RFA did not decrease the early recurrence rate, and this suggested that RFA may be not necessary for such patients. Furthermore, we made a multivariate analysis and figured that pretransplant RFA was the independent factor for recurrence.

Our study has limitations. First, the sample size is small and from a single-center institution. Larger multicenter studies are needed to determine whether pretransplant RFA can reduce recurrence in patients with HCC. Second, the value of postoperative CTCs in guiding pretransplant RFA should be analyzed in further study. For future studies, the 3-year and 5-year recurrence time and OS values should be calculated to obtain more convincing conclusions.

Conclusion

In conclusion, this study provides evidence that CTC results can be used for guiding pretransplant RFA for patients with HCC. Therefore, CTC result is a potentially promising biomarker and clinical indicator for administration of pretransplant RFA for HCC patients.

Declarations

Acknowledgement

This work was supported by the National Natural Science Foundation of China (81401324 and 81770410), the Science and Technology Planning Project of Guangdong Province (2016A020215048), the Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology (2013A061401007), the Guangdong Basic and Applied Basic Research Foundation (2020A1515011557, 2020A1515010903), and the Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) (2015B050501002), China.

References

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2018;391(10127):1301-14.
2. Gryziak M, Woźniak K, Kraj L, Stec R. Milestones in the treatment of hepatocellular carcinoma: A systematic review. Critical reviews in oncology/hematology. 2021;157:103179.

3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.

4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease. 1999;19(3):329-38.

5. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908-16.

6. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. Journal of hepatology. 2012;56(2):412-8.

7. Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nature reviews Gastroenterology & hepatology. 2017;14(4):203-17.

8. Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Annals of surgery. 2017;266(3):525-35.

9. Benson AB, 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7(4):350-91.

10. Zhang YJ, Chen MS. Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma. World journal of hepatology. 2010;2(4):146-50.

11. Habibollahi P, Sheth RA, Cressman ENK. Histological Correlation for Radiofrequency and Microwave Ablation in the Local Control of Hepatocellular Carcinoma (HCC) before Liver Transplantation: A Comprehensive Review. Cancers. 2020;13(1).

12. Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. Journal of gastrointestinal cancer. 2020;51(4):1127-32.

13. Chen Z, Lin X, Chen C, Chen Y, Zhao Q, Wu L, et al. Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation. Ann Transl Med. 2020;8(17):1067.

14. Qiu G, Jin Z, Chen X, Huang J. Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China. Global health & medicine. 2020;2(5):306-11.

15. Zhu F, Rhim H. Thermal ablation for hepatocellular carcinoma: what's new in 2019. Chinese clinical oncology. 2019;8(6):58.

16. Sarici B, Isik B, Yılmaz S. Management of Recurrent HCC After Liver Transplantation. Journal of gastrointestinal cancer. 2020;51(4):1197-9.
17. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: Management after the transplant. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020;20(2):333-47.

18. Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbeck's archives of surgery. 2017;402(6):863-71.

19. Yu L, Dai Z, Wang Z, Fan J, Zhou J. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology. 2011;81 Suppl 1:116-22.

20. Lai Q, Lesari S, Melandro F, Mennini G, Rossi M, Lerut J. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Translational gastroenterology and hepatology. 2017;2:72.

21. Vogl TJ, Riegelbauer LJ, Oppermann E, Kostantin M, Ackermann H, Trzmiel A, et al. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma. PloS one. 2021;16(2):e0246527.

22. Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, et al. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future oncology (London, England). 2015;11(21):2923-36.

23. Wang H, Stoecklein NH, Lin PP, Gires O. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget. 2017;8(1):1884-912.

24. de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World journal of gastroenterology. 2015;21(39):11185-98.

25. Lingiah VA, Niazi M, Olivo R, Paterno F, Guerrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. Journal of clinical and translational hepatology. 2020;8(1):69-75.

26. Asemota J, Saleh M, Igbinovia O, Burns D. A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. Cureus. 2020;12(7):e9191.

27. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10(3):374-94.

28. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol. 2000;156(1):57-63.

29. Lin E, Cao T, Nagrath S, King MR. Circulating Tumor Cells: Diagnostic and Therapeutic Applications. Annual review of biomedical engineering. 2018;20:329-52.

30. Agarwal A, Balic M, El-Ashry D, Cote RJ. Circulating Tumor Cells: Strategies for Capture, Analyses, and Propagation. Cancer journal (Sudbury, Mass). 2018;24(2):70-7.

31. Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, et al. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. Biochemical and biophysical research communications. 2017;492(3):507-12.
32. DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, et al. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Annals of surgery. 2020;271(4):616-24.

33. Romero-Gutiérrez M, Abanades Tercero M, Ruiz Martín J, Castro Limo JD, Artaza Varasa T, González de Frutos C, et al. Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2019;111(10):760-6.

34. Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine. 2019;98(4):e14070.

35. Wang S, Zheng Y, Liu J, Huo F, Zhou J. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2018;66(5):1-6.

36. Zhu ZX, Huang JW, Liao MH, Zeng Y. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Japanese journal of clinical oncology. 2016;46(12):1075-80.

37. Lee S, Kang TW, Song KD, Lee MW, Rhim H, Lim HK, et al. Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. Annals of surgery. 2019.

38. Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World journal of gastroenterology. 2019;25(32):4614-28.

39. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. European journal of radiology. 2008;67(2):336-47.

40. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182-236.

Tables

Table 1 Baseline characteristics of HCC patients for the entire study
| Variable                        | n   | %   |
|--------------------------------|-----|-----|
| **Gender**                     |     |     |
| Male                           | 74  | 93.7|
| Female                         | 5   | 6.3 |
| **Age (years)**                |     |     |
| &lt;50                          | 47  | 59.5|
| &lt;=50                        | 32  | 40.5|
| **CTC count**                  |     |     |
| &lt;1                           | 42  | 53.2|
| &lt;=1                          | 37  | 46.8|
| **Tumor number**               |     |     |
| &lt;3                           | 15  | 19.0|
| &lt;=3                          | 64  | 81.0|
| **Tumor diameter (cm)**        |     |     |
| &lt;3                           | 31  | 39.2|
| &lt;=3                          | 48  | 60.8|
| **PVT**                        |     |     |
| Yes                            | 16  | 20.3|
| No                             | 63  | 79.7|
| **MVI**                        |     |     |
| Yes                            | 15  | 19.0|
| No                             | 64  | 81.0|
| **Edmonson stage**             |     |     |
| I-II                           | 48  | 60.8|
| III-IV                         | 31  | 39.2|
| **Liver cirrhosis**            |     |     |
| Yes                            | 73  | 92.4|
| No                             | 6   | 7.6 |
| **Milan Criteria**             |     |     |
| Yes                            | 46  | 58.2|
| No                             | 33  | 41.7|
| **UCSF Criteria**              |     |     |
| Yes                            | 51  | 64.6|
| No                             | 28  | 35.4|
| **HBsAg (+)**                  |     |     |
| Yes                            | 65  | 82.3|
| No                             | 14  | 17.7|
| **AFP (ng/ml)**                |     |     |
| &lt;400                         | 20  | 25.3|
| &lt;=400                       | 59  | 74.7|
| **TNM stage**                  |     |     |
| I                              | 10  | 12.7|
| II                             | 23  | 29.1|
| III-IV                         | 46  | 58.2|
| **Transplantation treatment**  |     |     |
| Yes                            | 51  | 64.6|
| No                             | 28  | 35.4|
| **RFA only**                   |     |     |
| Yes                            | 18  | 22.8|
| No                             | 61  | 77.2|
| **Recurrence**                 |     |     |
| Yes                            | 20  | 25.3|
| No                             | 59  | 74.7|

Abbreviations: AFP, alpha-fetoprotein; CTC, circulating tumor cells; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasions; PVT, portal vein thrombosis; RFA, Radiofrequency Ablation; UCSF, University of California San Francisco.

**Table 2 Analysis of Relevant factors for Recurrence of HCC in 79 Patients**
| Variable                        | N= 79 | Recurrence (n=20) | Non-recurrence (n=59) | $\chi^2$ | P-value |
|--------------------------------|-------|-------------------|-----------------------|---------|---------|
| **Gender, n (%)**              |       |                   |                       |         |         |
| Male                           | 19(24.1) | 55(69.6)              | 0.08                  | 0.778  |
| Female                         | 1(1.3)   | 4(5.1)               |                       |         |
| **Age (years), n (%)**         |       |                   |                       |         |         |
| ≤50                            | 11(13.9) | 36(45.6)              | 0.224                | 0.636  |
| >50                            | 9(11.4)   | 23(29.1)             |                       |         |
| **CTC count, n (%)**           |       |                   |                       |         |         |
| ≤1                             | 15(19.0)  | 27(30.4)              | 5.128                | 0.024  |
| >1                             | 5(6.3)    | 32(40.5)             |                       |         |
| **Tumor number, n (%)**        |       |                   |                       |         |         |
| ≤3                             | 7(8.9)    | 8(10.1)              | 4.464                | 0.035  |
| >3                             | 13(16.5)  | 51(64.6)             |                       |         |
| **PVT, n (%)**                 |       |                   |                       |         |         |
| Yes                            | 6(7.6)    | 10(12.7)             | 1.575                | 0.209  |
| No                             | 14(17.7)  | 49(62.0)             |                       |         |
| **MVI, n (%)**                 |       |                   |                       |         |         |
| Yes                            | 7(8.9)    | 10(12.7)             | 2.882                | 0.090  |
| No                             | 13(16.5)  | 49(62.0)             |                       |         |
| **Edmonson stage, n (%)**      |       |                   |                       |         |         |
| I-II                           | 9(11.4)   | 39(49.4)             | 2.790                | 0.095  |
| III-IV                         | 11(13.9)  | 20(25.3)             |                       |         |
| **Liver cirrhosis, n (%)**     |       |                   |                       |         |         |
| Yes                            | 15(19.0)  | 58(73.4)             | 11.559               | 0.001  |
| No                             | 5(6.3)    | 1(1.3)               |                       |         |
| **Milan Criteria, n (%)**      |       |                   |                       |         |         |
| Yes                            | 6(7.6)    | 40(50.6)             | 8.773                | 0.003  |
| No                             | 14(17.7)  | 19(24.0)             |                       |         |
| **UCSF Criteria, n (%)**       |       |                   |                       |         |         |
| Yes                            | 7(8.8)    | 44(55.6)             | 10.225               | 0.001  |
| No                             | 13(16.4)  | 15(18.9)             |                       |         |
| **HBsAg (+), n (%)**           |       |                   |                       |         |         |
| Yes                            | 16(20.3)  | 49(62.0)             | 0.095                | 0.757  |
| No                             | 4(5.1)    | 10(12.7)             |                       |         |
| **RFA only, n (%)**            |       |                   |                       |         |         |
| Yes                            | 2(2.5)    | 16(20.3)             | 2.448                | 0.115  |
| No                             | 18(22.8)  | 43(54.4)             |                       |         |
| **AFP (ng/ml), n (%)**         |       |                   |                       |         |         |
| ≤400                           | 7(8.9)    | 13(16.5)             | 1.328                | 0.249  |
| >400                           | 13(16.5)  | 46(58.2)             |                       |         |
| **TNM stage, n (%)**           |       |                   |                       |         |         |
| I                              | 0        | 10(12.7)             | 6.334                | 0.042  |
| II                             | 4(5.1)    | 19(24.1)             |                       |         |
| III-IV                         | 16(20.3)  | 30(38.0)             |                       |         |

Bold P-values indicates statistical significance.

Abbreviations: AFP, alpha-fetoprotein; CTC, circulating tumor cells; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasions; PVT, portal vein thrombosis; RFA, Radiofrequency Ablation; UCSF, University of California San Francisco.

**Table 3 Baseline characteristics in HCC patients with/without RFA**
| Variable                        | N=79   | RFA (n=18) | non-RFA (n=61) | \(\chi^2\) | P-value |
|--------------------------------|--------|------------|----------------|-----------|---------|
| Gender, n (%)                  |        |            |                |           |         |
| Male                           | 16(20.3) | 2(2.5)    | 58(73.4)       | 3(3.8)    | 0.899   | 0.343   |
| Female                         | 2(2.5)  | 56(73.4)  | 22(27.8)       | 3(3.8)    | 2.191   | 0.139   |
| Age (years), n (%)             |        |            |                |           |         |
| \(\leq 50\)                   | 8(10.1) | 39(49.4)  | 22(27.8)       | 58(73.4)  | 2.191   | 0.139   |
| \(\leq 50\)                   | 10(12.7)| 22(27.8)  | 22(27.8)       | 58(73.4)  | 2.191   | 0.139   |
| CTC count, n (%)               |        |            |                |           |         |
| \(\leq 1\)                    | 8(10.1) | 34(43.0)  | 27(34.2)       | 58(73.4)  | 0.712   | 0.399   |
| \(\leq 1\)                    | 10(12.7)| 27(34.2)  | 27(34.2)       | 58(73.4)  | 0.712   | 0.399   |
| Tumor number, n (%)            |        |            |                |           |         |
| \(\leq 3\)                    | 1(1.3)  | 14(17.7)  | 47(59.5)       | 58(73.4)  | 2.734   | 0.098   |
| \(\leq 3\)                    | 17(21.5)| 47(59.5)  | 47(59.5)       | 58(73.4)  | 2.734   | 0.098   |
| Tumor diameter (cm), n (%)     |        |            |                |           |         |
| \(\leq 3\)                    | 6(7.6)  | 9(11.4)   | 52(65.8)       | 58(73.4)  | 3.119   | 0.077   |
| \(\leq 3\)                    | 12(15.2)| 52(65.8)  | 52(65.8)       | 58(73.4)  | 3.119   | 0.077   |
| PVT, n (%)                     |        |            |                |           |         |
| Yes                            | 3(3.8)  | 13(16.5)  | 13(16.5)       | 58(73.4)  | 0.186   | 0.667   |
| No                             | 15(19.0)| 48(60.8)  | 48(60.8)       | 58(73.4)  | 0.186   | 0.667   |
| MVI, n (%)                     |        |            |                |           |         |
| Yes                            | 3(3.8)  | 12(15.2)  | 49(62.0)       | 58(73.4)  | 0.082   | 0.775   |
| No                             | 15(19.0)| 49(62.0)  | 49(62.0)       | 58(73.4)  | 0.082   | 0.775   |
| Edmonson stage, n (%)          |        |            |                |           |         |
| I-II                           | 11(13.9)| 37(46.8)  | 24(30.4)       | 58(73.4)  | 0.001   | 0.972   |
| III-IV                         | 7(8.9)  | 24(30.4)  | 24(30.4)       | 58(73.4)  | 0.001   | 0.972   |
| Liver cirrhosis, n (%)         |        |            |                |           |         |
| Yes                            | 17(21.5)| 56(71.0)  | 56(71.0)       | 58(73.4)  | 0.138   | 0.710   |
| No                             | 1(1.3)  | 5(6.3)    | 5(6.3)         | 58(73.4)  | 0.138   | 0.710   |
| Milan Criteria, n (%)          |        |            |                |           |         |
| Yes                            | 14(11.4)| 32(40.5)  | 29(36.7)       | 58(73.4)  | 3.663   | 0.056   |
| No                             | 4(5.0)  | 29(36.7)  | 29(36.7)       | 58(73.4)  | 3.663   | 0.056   |
| UCSF Criteria, n (%)           |        |            |                |           |         |
| Yes                            | 15(18.9)| 36(45.5)  | 25(31.6)       | 58(73.4)  | 3.592   | 0.058   |
| No                             | 3(3.7)  | 25(31.6)  | 25(31.6)       | 58(73.4)  | 3.592   | 0.058   |
| HBsAg (+), n (%)               |        |            |                |           |         |
| Yes                            | 14(17.7)| 51(64.6)  | 10(12.7)       | 58(73.4)  | 0.324   | 0.569   |
| No                             | 4(5.1)  | 10(12.7)  | 10(12.7)       | 58(73.4)  | 0.324   | 0.569   |
| AFP (ng/ml), n (%)             |        |            |                |           |         |
| \(\leq 400\)                  | 3(3.8)  | 17(21.5)  | 44(55.7)       | 58(73.4)  | 0.922   | 0.337   |
| \(\leq 400\)                  | 15(19.0)| 44(55.7)  | 44(55.7)       | 58(73.4)  | 0.922   | 0.337   |
| TNM stage, n (%)               |        |            |                |           |         |
| I                              | 1(1.3)  | 9(11.4)   | 16(20.3)       | 58(73.4)  | 1.723   | 0.423   |
| II                             | 7(8.9)  | 16(20.3)  | 16(20.3)       | 58(73.4)  | 1.723   | 0.423   |
| III-IV                         | 10(12.7)| 36(45.6)  | 36(45.6)       | 58(73.4)  | 1.723   | 0.423   |

Abbreviations: AFP, alpha-fetoprotein; CTC, circulating tumor cells; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasions; PVT, portal vein thrombosis; RFA, Radiofrequency Ablation; UCSF, University of California San Francisco.

Table 4 Multivariate analysis to identify independent risk factors of progression free survival and overall survival in CTC-positive HCC patients.
Bold $P$-values indicates statistical significance.
Abbreviations: AFP, alpha-fetoprotein; CTC, circulating tumor cells; HBsAg, Hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasions; PVT, portal vein thrombosis; RFA, Radiofrequency Ablation; UCSF, University of California San Francisco.

**Figures**

**Figure 1**
Flow chart for patients’ selection in this study
Figure 2

Comparison of PFS and OS between different groups of HCC patients. A: PFS between CTC-positive and CTC-negative groups; B: OS between CTC-positive and CTC-negative groups; C: PFS between RFA and non-RFA groups in CTC-positive HCC patients; D: PFS between RFA and non-RFA groups in CTC-negative HCC patients; E: OS between RFA and non-RFA groups in CTC-positive HCC patients; F: OS between RFA and non-RFA groups in CTC-negative HCC patients.
Figure 3

Kaplan-Meier analysis of PFS in subgroups of CTC-positive HCC patients. A Tumor size <3cm; B Without PVT; C Without MVI; D Tumor number ≤3; E Tumor stage (I-II); F Edmonson stage (I-II); G With cirrhosis; H HBsAg (+). PVT, portal vein thrombosis; MVI, microvascular invasions; HBsAg, Hepatitis B surface antigen.